Skip to main navigation
Ardelyx logo2
  • Who We Are
  • Our Science
  • Our Pipeline
  • Patients & Families
  • Investors
  • Join Us
  • MENU
  • HOME
Select Page

News & Events

  • IR HOME
  • NEWS & EVENTS
    • OVERVIEW
    • PRESS RELEASES
    • EVENTS & PRESENTATIONS
  • STOCK INFORMATION
    • OVERVIEW
    • HISTORIC STOCK LOOKUP
    • INVESTMENT CALCULATOR
    • ANALYST COVERAGE
  • FINANCIALS & FILINGS
    • OVERVIEW
    • SEC FILINGS
  • CORPORATE GOVERNANCE
    • OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • COMMITTEE COMPOSITION
  • CONTACT IR
  • IR HOME
  • NEWS & EVENTS
    • OVERVIEW
    • PRESS RELEASES
    • EVENTS & PRESENTATIONS
  • STOCK INFORMATION
    • OVERVIEW
    • HISTORIC STOCK LOOKUP
    • INVESTMENT CALCULATOR
    • ANALYST COVERAGE
  • FINANCIALS & FILINGS
    • OVERVIEW
    • SEC FILINGS
  • CORPORATE GOVERNANCE
    • OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • COMMITTEE COMPOSITION
  • CONTACT IR

News & Events

Press Releases
Apr 14, 2021
Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan
Read More
Apr 12, 2021
Ardelyx Announces Upcoming Data Presentation at ISN World Congress of Nephrology 2021
Read More
Mar 30, 2021
Ardelyx Announces Poster Presentations, Educational Symposium, and Exhibitor Showcase at National Kidney Foundation 2021 Virtual Spring Clinical Meetings
Read More
View All Press Releases
Events & Presentations
Feb 24, 2021 at 3:00 PM EST
10th Annual SVB Leerink Global Healthcare Conference
View All Events
FAQs
Email Alerts
Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Boston Area
200 West Street, 4th Floor
Waltham, MA 02451

Phone: 510.745.1700

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com

  • Follow
  • Follow

© 2021 Ardelyx®
Terms & Conditions · Privacy Policy
Expanded Access · Forward Looking Statements

SITE DESIGN BY D&CO
  • Facebook
  • LinkedIn
  • Twitter
  • RSS